Beate Timmermann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Beate Timmermann has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Gudrun Goitein
Center for Proton Radiation Therapy, Paul Scherrer Institute, Villigen, Switzerland
3 shared publicationsMarkus Weiss
University Children's Hospital of Zurich, Switzerland
3 shared publicationsRolf-Dieter Kortmann
Department of Radiation Oncology, University of Leipzig, Germany
3 shared publicationsAndreas Schuck
Department of Radiation Oncology, University of Münster, Münster, Germany
2 shared publicationsAntony Jonathan Lomax
Center for Proton Radiation Therapy, Paul Scherrer Institute, Villigen, Switzerland
2 shared publications- Brigitte Bison
Institute of Neuroradiology, University Hospital of Wuerzburg, Wuerzburg, Germany
2 shared publications
Latest Publications
- 22 June 2018
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 20 (suppl_2) , i109
LGG-23. REPEATED PROGRESSIONS IN PEDIATRIC CHIASMATIC-HYPOTHALAMIC GLIOMAS (CHG): CAN WE IDENTIFY SUCCESSFUL TREATMENT STRATEGIES?
Recommendations for primary treatment of pediatric CHG are well established, but comprehensive therapeutic strategies for subsequent progressive disease are needed. We evaluated salvage therapies applied within the German/Swiss SIOP-LGG-2004/LGG-register cohort. 446 patients with CHG among 2589 patients with low-grade glioma were registered between 2004 and 2015. Neurofibromatosis type 1: 209; histology: 159 pilocytic astrocytomas, 18 pilomyxoid astrocytomas, 27 other histologies and 242 radiological diagnosis. Resection (complete/subtotal/partial) was achieved in 115, biopsy in 89 patients. Only 131/446 patients remained observed without treatment for up to12.8 years. First non-surgical treatment was chemotherapy (ChT) for 268 (263 vincristine/carboplatin ±etoposide) and radiotherapy (RT) for 47. After primary treatment 136/315 patients progressed (median time 2.2 years), of whom 107 received second- (85ChT, 22RT), 54 third- (39ChT, 15RT), 15 fourth- (11ChT, 4RT) and 5 fifth-line therapy (2ChT, 3RT). Five-year overall survival (OS) of the complete cohort is 96.8%. Although 23/53 infants (age <1year) and 21/44 patients with dissemination needed 3-5 therapies, 5-year-OS for infants is still 83.7% and 84.9% for dissemination, respectively. While successive treatments mirrored the distribution of general options, the percentage of patients receiving RT increased up to 30-60% for fourth and fifth therapy. Multiple chemotherapies do not seem to hamper the effect of subsequent radiotherapy. Following vincristine/carboplatin ±etoposide second-line platinum-based ChT achieved 53.4% 2-year progression-free survival vs. 30.3% with vinblastine. Progression/relapse of pediatric CHG following first-line standard treatment still allows disease control for most patients with multiple treatment lines. Future studies should focus upon the effect on vision and integrate targeted treatment.
- 22 June 2018
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 20 (suppl_2) , i109
LGG-23. REPEATED PROGRESSIONS IN PEDIATRIC CHIASMATIC-HYPOTHALAMIC GLIOMAS (CHG): CAN WE IDENTIFY SUCCESSFUL TREATMENT STRATEGIES?
Recommendations for primary treatment of pediatric CHG are well established, but comprehensive therapeutic strategies for subsequent progressive disease are needed. We evaluated salvage therapies applied within the German/Swiss SIOP-LGG-2004/LGG-register cohort. 446 patients with CHG among 2589 patients with low-grade glioma were registered between 2004 and 2015. Neurofibromatosis type 1: 209; histology: 159 pilocytic astrocytomas, 18 pilomyxoid astrocytomas, 27 other histologies and 242 radiological diagnosis. Resection (complete/subtotal/partial) was achieved in 115, biopsy in 89 patients. Only 131/446 patients remained observed without treatment for up to12.8 years. First non-surgical treatment was chemotherapy (ChT) for 268 (263 vincristine/carboplatin ±etoposide) and radiotherapy (RT) for 47. After primary treatment 136/315 patients progressed (median time 2.2 years), of whom 107 received second- (85ChT, 22RT), 54 third- (39ChT, 15RT), 15 fourth- (11ChT, 4RT) and 5 fifth-line therapy (2ChT, 3RT). Five-year overall survival (OS) of the complete cohort is 96.8%. Although 23/53 infants (age <1year) and 21/44 patients with dissemination needed 3-5 therapies, 5-year-OS for infants is still 83.7% and 84.9% for dissemination, respectively. While successive treatments mirrored the distribution of general options, the percentage of patients receiving RT increased up to 30-60% for fourth and fifth therapy. Multiple chemotherapies do not seem to hamper the effect of subsequent radiotherapy. Following vincristine/carboplatin ±etoposide second-line platinum-based ChT achieved 53.4% 2-year progression-free survival vs. 30.3% with vinblastine. Progression/relapse of pediatric CHG following first-line standard treatment still allows disease control for most patients with multiple treatment lines. Future studies should focus upon the effect on vision and integrate targeted treatment.
- 22 June 2018
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 20 (suppl_2) , i107
LGG-15. REQUIREMENT OF ADJUVANT TREATMENT IN CHILDHOOD LOW GRADE GLIOMAS (LGG) OF THE SPINAL CORD: EXPERIENCES FROM THE GERMAN LGG STUDY GROUP
To evaluate the risk of progression and the proportion of patients with childhood spinal cord LGG requiring multiple treatments. Clinical data-sets of 117 pediatric patients (male, n=74; median age 8 [range, 0.7-16.2] years) registered in the prospective multicenter trials HIT-LGG-1996 (n=36), SIOP-LGG-2004 (n=56) and the subsequent LGG-Interim registry (n=25) were analyzed (median follow-up 6.6 years). 107 patients were observed following complete (n=22) or partial resection (n=73), biopsy (n=20), or radiologic diagnosis only (n=2). 10 patients received initial chemotherapy (n=8) or irradiation (n=2). 60 of 107 initially observed patients (56%) developed radiological/clinical progressive disease. Median time to progression was 7 months (range, 0.1-11 years) after diagnosis. 10-year event-free survival (EFS) of the entire cohort was 33.5 ± 5.5%. Overall, 43 patients underwent 2-4 surgical interventions and 42 patients (36%) required adjuvant treatment (chemotherapy, n=21; radiotherapy, n=11; multimodal treatment, n=10). 10-year PFS after chemo- and radiotherapy was 37.7 ± 9.7% and 59.5 ± 16.2%, respectively. Disease control (median, 5.1 years) was achieved in 70 patients (67%) after one (n=52) or repeated (n=18) resections, in 12/21 after chemotherapy, 11/11 after irradiation and 5/10 patients with multimodal treatment. 10-year overall survival (OS) was 92.7 ± 2.8%. Patients with dissemination (n=16) had inferior OS and EFS, while age ≥11 years and complete resection were favorable factors for EFS. The majority of children with spinal LGG experience progressive disease, even after years, and more than a third require repeated resections and/or adjuvant treatment. Despite frequent progression following adjuvant chemo-/radiotherapy, long-term disease control is achieved even in cases with multiple progressions.
- 22 June 2018
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 20 (suppl_2) , i107
LGG-15. REQUIREMENT OF ADJUVANT TREATMENT IN CHILDHOOD LOW GRADE GLIOMAS (LGG) OF THE SPINAL CORD: EXPERIENCES FROM THE GERMAN LGG STUDY GROUP
To evaluate the risk of progression and the proportion of patients with childhood spinal cord LGG requiring multiple treatments. Clinical data-sets of 117 pediatric patients (male, n=74; median age 8 [range, 0.7-16.2] years) registered in the prospective multicenter trials HIT-LGG-1996 (n=36), SIOP-LGG-2004 (n=56) and the subsequent LGG-Interim registry (n=25) were analyzed (median follow-up 6.6 years). 107 patients were observed following complete (n=22) or partial resection (n=73), biopsy (n=20), or radiologic diagnosis only (n=2). 10 patients received initial chemotherapy (n=8) or irradiation (n=2). 60 of 107 initially observed patients (56%) developed radiological/clinical progressive disease. Median time to progression was 7 months (range, 0.1-11 years) after diagnosis. 10-year event-free survival (EFS) of the entire cohort was 33.5 ± 5.5%. Overall, 43 patients underwent 2-4 surgical interventions and 42 patients (36%) required adjuvant treatment (chemotherapy, n=21; radiotherapy, n=11; multimodal treatment, n=10). 10-year PFS after chemo- and radiotherapy was 37.7 ± 9.7% and 59.5 ± 16.2%, respectively. Disease control (median, 5.1 years) was achieved in 70 patients (67%) after one (n=52) or repeated (n=18) resections, in 12/21 after chemotherapy, 11/11 after irradiation and 5/10 patients with multimodal treatment. 10-year overall survival (OS) was 92.7 ± 2.8%. Patients with dissemination (n=16) had inferior OS and EFS, while age ≥11 years and complete resection were favorable factors for EFS. The majority of children with spinal LGG experience progressive disease, even after years, and more than a third require repeated resections and/or adjuvant treatment. Despite frequent progression following adjuvant chemo-/radiotherapy, long-term disease control is achieved even in cases with multiple progressions.
- Open Access
- 21 April 2008
- Published by Springer Nature in Radiation Oncology
- Vol. 3 (1) , 10
Study protocol of the German "Registry for the Detection of Late Sequelae after Radiotherapy in Childhood and Adolescence" (RiSK)
Background: Late effects after radiotherapy in childhood and adolescence have mainly been characterized retrospectively with small patient numbers. However, these analyses are limited due to little information regarding organ dose levels in many cases. To overcome this limitation, the German Group of Paediatric Radiation Oncology (APRO) established the „Registry for the evaluation of late side effects after radiation in childhood and adolescence” (RiSK). The study protocol and the documentation forms are given in this publication. Methods/Design: Radiation parameters including detailed organ doses as well as toxicity evaluations are collected prospectively from centres all over Germany. Standardized documentation forms are used. These forms are given in an English and German version as additional files to this publication. Documentation is planned for all children who receive radiotherapy in one of the therapy trials of the "German Society of Paediatric Oncology and Haematology (GPOH)". The study started in a pilot phase in June 2001 in few centres. Since 2004 documentation has been performed all over Germany and is still on-going. Discussion: To our knowledge, "RiSK" is the only multi-centre study that evaluates radiation associated side effects prospectively with detailed information about organ dose levels. With ongoing recruitment and prolongation of follow-up powerful data will be obtained in a few years. A broad use and international cooperation are welcome.
- 21 April 2008
- Published by Springer Nature in Radiation Oncology
- Vol. 3 (1) , 10
Open AccessStudy protocol of the German "Registry for the Detection of Late Sequelae after Radiotherapy in Childhood and Adolescence" (RiSK)
Background: Late effects after radiotherapy in childhood and adolescence have mainly been characterized retrospectively with small patient numbers. However, these analyses are limited due to little information regarding organ dose levels in many cases. To overcome this limitation, the German Group of Paediatric Radiation Oncology (APRO) established the „Registry for the evaluation of late side effects after radiation in childhood and adolescence” (RiSK). The study protocol and the documentation forms are given in this publication. Methods/Design: Radiation parameters including detailed organ doses as well as toxicity evaluations are collected prospectively from centres all over Germany. Standardized documentation forms are used. These forms are given in an English and German version as additional files to this publication. Documentation is planned for all children who receive radiotherapy in one of the therapy trials of the "German Society of Paediatric Oncology and Haematology (GPOH)". The study started in a pilot phase in June 2001 in few centres. Since 2004 documentation has been performed all over Germany and is still on-going. Discussion: To our knowledge, "RiSK" is the only multi-centre study that evaluates radiation associated side effects prospectively with detailed information about organ dose levels. With ongoing recruitment and prolongation of follow-up powerful data will be obtained in a few years. A broad use and international cooperation are welcome.
- 1 December 2007
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 183 (12) , 685-688
Novel Technique of Craniospinal Axis Proton Therapy with the Spot-Scanning System
- 1 December 2007
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 183 (12) , 685-688
Novel Technique of Craniospinal Axis Proton Therapy with the Spot-Scanning System
- 1 February 2007
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 67 (2) , 497-504
Spot-scanning proton therapy for malignant soft tissue tumors in childhood: First experiences at the Paul Scherrer Institute
- 1 February 2007
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 67 (2) , 497-504
Spot-scanning proton therapy for malignant soft tissue tumors in childhood: First experiences at the Paul Scherrer Institute
- 1 November 2006
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 182 (11) , 653-659
Protonentherapie mit „Spot-Scanning“ bei Rhabdomyosarkomen im frühen Kindesalter
Die Durchführbarkeit und Verträglichkeit der Spot-Scanning-Protonentherapie in tiefer Sedierung bei Kindern mit Rhabdomyosarkomen (RMS) sollten geprüft werden. Seit 2004 werden junge Kinder am Paul Scherrer Institut (PSI), Villigen, Schweiz, auch in tiefer Sedierung mit Protonen bestrahlt. Ausgewertet wurden Kinder unter 5 Jahren mit RMS im Bereich des Kopfes und Körperstamms. Alle Kinder waren in eine Therapieoptimierungsstudie eingeschlossen und wurden prospektiv hinsichtlich der Verträglichkeit der Bestrahlung untersucht. Neun Kinder im medianen Alter von 1,9 Jahren wurden untersucht (sechs embryonale RMS und je ein alveoläres, undifferenziertes und nicht klassifizierbares RMS). Die Lokalisationen waren parameningeal (n = 4), orbital (n = 3), Kopf-Hals-Bereich (n = 1) und Prostata (n = 1). Bei allen Kindern lag ein IRS-Stadium III vor. Die Bestrahlung erfolgte ausschließlich mit Protonen (Gesamtdosen 46–54 CGE [Cobalt-Gray-Äquivalent]). Akuttoxizitäten Grad 3 oder 4 nach RTOG/EORTC traten ausschließlich im Bereich des Knochenmarks auf. Die Protonentherapie bei RMS im frühen Kindesalter war problemlos durchführbar und hervorragend verträglich. Prospektive, standardisierte Erhebungen von Spättoxizität und Lebensqualität sind essentiell. To evaluate the feasibility and acute toxicity of spot-scanning proton therapy under deep sedation in young children with rhabdomyosarcomas (RMS). Since 2004, children requiring sedation can be admitted for proton therapy at Paul Scherrer Institute (PSI), Villigen, Switzerland. Children under 5 years of age with RMS of the head and the trunk were analyzed. All children were enrolled in a multidisciplinary treatment protocol and prospective, standardized evaluation of side effects was performed. Nine children were included aged 0.9–3.8 years (embryonal RMS in six, and alveolar, undifferentiated or nonclassified in one each). The tumor site was parameningeal (n = 4), orbital (n = 3), head and neck (n = 1), and prostate (n = 1). All children were in IRS group III. Total proton dose was 46–54 CGE (cobalt-gray equivalent). Only the myelotoxicity exceeded grade 3 or 4 (RTOG/EORTC). Proton therapy for RMS in early children is feasible and well tolerated. The prospective standardized evaluation of toxicity and quality of life needs to be continued.
- 1 November 2006
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 182 (11) , 653-659
Protonentherapie mit „Spot-Scanning“ bei Rhabdomyosarkomen im frühen Kindesalter
Die Durchführbarkeit und Verträglichkeit der Spot-Scanning-Protonentherapie in tiefer Sedierung bei Kindern mit Rhabdomyosarkomen (RMS) sollten geprüft werden. Seit 2004 werden junge Kinder am Paul Scherrer Institut (PSI), Villigen, Schweiz, auch in tiefer Sedierung mit Protonen bestrahlt. Ausgewertet wurden Kinder unter 5 Jahren mit RMS im Bereich des Kopfes und Körperstamms. Alle Kinder waren in eine Therapieoptimierungsstudie eingeschlossen und wurden prospektiv hinsichtlich der Verträglichkeit der Bestrahlung untersucht. Neun Kinder im medianen Alter von 1,9 Jahren wurden untersucht (sechs embryonale RMS und je ein alveoläres, undifferenziertes und nicht klassifizierbares RMS). Die Lokalisationen waren parameningeal (n = 4), orbital (n = 3), Kopf-Hals-Bereich (n = 1) und Prostata (n = 1). Bei allen Kindern lag ein IRS-Stadium III vor. Die Bestrahlung erfolgte ausschließlich mit Protonen (Gesamtdosen 46–54 CGE [Cobalt-Gray-Äquivalent]). Akuttoxizitäten Grad 3 oder 4 nach RTOG/EORTC traten ausschließlich im Bereich des Knochenmarks auf. Die Protonentherapie bei RMS im frühen Kindesalter war problemlos durchführbar und hervorragend verträglich. Prospektive, standardisierte Erhebungen von Spättoxizität und Lebensqualität sind essentiell. To evaluate the feasibility and acute toxicity of spot-scanning proton therapy under deep sedation in young children with rhabdomyosarcomas (RMS). Since 2004, children requiring sedation can be admitted for proton therapy at Paul Scherrer Institute (PSI), Villigen, Switzerland. Children under 5 years of age with RMS of the head and the trunk were analyzed. All children were enrolled in a multidisciplinary treatment protocol and prospective, standardized evaluation of side effects was performed. Nine children were included aged 0.9–3.8 years (embryonal RMS in six, and alveolar, undifferentiated or nonclassified in one each). The tumor site was parameningeal (n = 4), orbital (n = 3), head and neck (n = 1), and prostate (n = 1). All children were in IRS group III. Total proton dose was 46–54 CGE (cobalt-gray equivalent). Only the myelotoxicity exceeded grade 3 or 4 (RTOG/EORTC). Proton therapy for RMS in early children is feasible and well tolerated. The prospective standardized evaluation of toxicity and quality of life needs to be continued.
- 1 April 2006
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (10) , 1554-1560
Role of Radiotherapy in Supratentorial Primitive Neuroectodermal Tumor in Young Children: Results of the German HIT-SKK87 and HIT-SKK92 Trials
Purpose To assess the outcome of young children with supratentorial primitive neuroectodermal tumor (stPNET) treated by intensive postoperative chemotherapy alone compared with treatment with chemotherapy and delayed radiotherapy (RT). Patients and Methods From 1987 to 1992, children younger than 3 years of age with stPNET were enrolled in the HIT-SKK87 trial in Germany and Austria. After surgery, low-risk patients received maintenance chemotherapy before RT. In high-risk patients, intensive induction chemotherapy was followed by maintenance chemotherapy until delayed RT was initiated. In the following trial, HIT-SKK92 methotrexate-based chemotherapy was applied. In children with complete remission after three cycles, therapy was finished without irradiation. Otherwise, radiotherapy or salvage chemotherapy was administered. Results Twenty-nine children were eligible (age, 3.0 to 37.0 months). All children received chemotherapy. In 15 children, no RT was administered. Four children had tumor progression du...
- 1 April 2006
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (10) , 1554-1560
Role of Radiotherapy in Supratentorial Primitive Neuroectodermal Tumor in Young Children: Results of the German HIT-SKK87 and HIT-SKK92 Trials
Purpose To assess the outcome of young children with supratentorial primitive neuroectodermal tumor (stPNET) treated by intensive postoperative chemotherapy alone compared with treatment with chemotherapy and delayed radiotherapy (RT). Patients and Methods From 1987 to 1992, children younger than 3 years of age with stPNET were enrolled in the HIT-SKK87 trial in Germany and Austria. After surgery, low-risk patients received maintenance chemotherapy before RT. In high-risk patients, intensive induction chemotherapy was followed by maintenance chemotherapy until delayed RT was initiated. In the following trial, HIT-SKK92 methotrexate-based chemotherapy was applied. In children with complete remission after three cycles, therapy was finished without irradiation. Otherwise, radiotherapy or salvage chemotherapy was administered. Results Twenty-nine children were eligible (age, 3.0 to 37.0 months). All children received chemotherapy. In 15 children, no RT was administered. Four children had tumor progression du...
- 1 December 2005
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 77 (3) , 278-285
Role of radiotherapy in anaplastic ependymoma in children under age of 3 years: Results of the prospective German brain tumor trials HIT-SKK 87 and 92
- 1 December 2005
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 77 (3) , 278-285
Role of radiotherapy in anaplastic ependymoma in children under age of 3 years: Results of the prospective German brain tumor trials HIT-SKK 87 and 92